Open AccessNR2 antibodies as diagnostic and prognostic stroke biomarker
Author(s) -
М. П. Топузова,
Т. М. Алексеева,
Е. Б. Панина,
Т. В. Вавилова,
М. Л. Поспелова,
Nataliya Ivanova
Publication year - 2020
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2020-26-1-27-36
Subject(s) - biomarker , medicine , stroke (engine) , antibody , ischemic stroke , intensive care medicine , oncology , bioinformatics , immunology , biology , mechanical engineering , biochemistry , ischemia , engineering
Given the high percentage of disability and mortality resulting from a stroke, search of new ways to improve early diagnosis and optimize therapeutic approaches is highly relevant. The article reviews the studies of NR2 antibodies to glutamate N-methyl-D-aspartate (NMDA) receptors as a biomarker in acute stroke. The review shows that this biomarker is suitable for determining the presence of ischemic process in the brain and the degree of destruction of brain tissue, both in the first hours of stroke and at follow-up. In addition, the analysis of NR2 antibodies can be informative to predict the worsening, the increase in the locus size, which can contribute to the timely correction of treatment and will improve the effectiveness of the therapy. The prognostic potential of NR2 antibodies can be used for personalized therapeutic approach. However, currently the lack of studies of NR2 antibodies in acute stroke requires further study of this biomarker.